Navigation Links
Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
Date:1/6/2009

Foam technology also forms the basis of multiple development projects providing Pacira an opportunity to expand its pipeline. Pacira owns two cGMP production facilities which produce the two approved products, EXPAREL clinical development and all pipeline materials.

Additional information about Pacira is available at http://www.pacira.com.

This news release contains forward-looking statements that involve risks and uncertainties, including statements relating to initiation and progress of the Company's clinical trial programs and the preliminary results from the clinical trials. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward- looking statements contained in the release and anticipated presentation.

Pacira Contact: Taunia Markvicka

Vice President, Commercial Development

973-254-3565


'/>"/>
SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Alberta , Sept. 16, 2014  Wearable ... billion industry in less than two years, producing ... the way. A huge opportunity exists for leveraging ... Vivametrica ( http://vivametrica.com/our-video/ ) introduced a first-of-its-kind wearable ... based on years of clinical research linking activity ...
(Date:9/16/2014)...  Eli Lilly and Company (NYSE: ... to co-develop and commercialize AZD3293, an oral beta ... as a potential treatment for Alzheimer,s disease. ... by the accumulation of amyloid plaque in the ... development of beta-amyloid. Inhibiting BACE is expected to ...
(Date:9/15/2014)... PARIS and NEW YORK ... company Pharnext SAS and the Hereditary Neuropathy Foundation (HNF) ... increase the awareness around Charcot-Marie-Tooth (CMT) disease and support ... community. Pharnext will provide financial support ... design and development of a specific section in the ...
Breaking Medicine Technology:Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 2Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 3Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 3Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 4Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 4
... Accelerated Community Oncology,Research Network(TM) (ACORN) will ... Guardian EDC(TM); PACE(TM) PRO System; and,proprietary oncology-focused ... Meeting,June 22-26, in Boston, MA., (Logo: ... 2008 the company announced its Contract Research ...
... iCAD, Inc. (Nasdaq:,ICAD), an industry-leading provider of ... cancer, today announced it has,initiated a clinical study ... partnership with ACR Image Metrix, a subsidiary of ... Image Metrix, having completed the,development portion of the ...
Cached Medicine Technology:ACORN Showcases Oncology CRO, EDC, PRO and Data Warehouse at 44th Annual DIA Meeting 2iCAD Initiates Clinical Study of Its Virtual Colonoscopy CAD in Partnership with ACR Image Metrix 2iCAD Initiates Clinical Study of Its Virtual Colonoscopy CAD in Partnership with ACR Image Metrix 3iCAD Initiates Clinical Study of Its Virtual Colonoscopy CAD in Partnership with ACR Image Metrix 4
(Date:9/16/2014)... 16, 2014 LiveOps, the global ... solutions, announced today that the company has received ... for the creation of a social learning ecosystem ... Hall Group honors companies that have successfully developed ... tools that have helped companies achieve measurable results. ...
(Date:9/16/2014)... 16, 2014 Former Major League Baseball ... undergoing successful heart transplantation surgery at Allegheny General Hospital ... spent most of his 16-year baseball career with the ... commentator for Root Sports Pittsburgh, was discharged home on ... Bailey, MD, surgical director of AGH’s heart transplant program. ...
(Date:9/16/2014)... September 15, 2014Patients with inoperable, early-stage lung cancer ... a five-year survival rate of 40 percent, according ... for Radiation Oncology,s (ASTRO,s) 56th Annual Meeting. Such ... historically conventional RT resulted in poor tumor control ... is an update of RTOG 0236, originally published ...
(Date:9/16/2014)... who tend to be on the heavy side. Researchers ... found that seven in every ten obese adults underestimate ... this mistake much less often. Mothers of overweight or ... as youngsters misjudge their obese mothers, size, says lead ... a study in the Journal of General Internal ...
(Date:9/16/2014)... Poster Discussion abstracts to be presented at the ESMO ... September 2014 at 12:00 (CEST) to give you a ... European medical oncology Congress, under the leading theme Precision ... point where genuinely targeted therapy is now possible for ... we are all working towards a common goal --improved ...
Breaking Medicine News(10 mins):Health News:LiveOps Wins Silver At The 2014 Brandon Hall Group Excellence In Learning Awards For Best Use Of Social/Collaborative Learning 2Health News:LiveOps Wins Silver At The 2014 Brandon Hall Group Excellence In Learning Awards For Best Use Of Social/Collaborative Learning 3Health News:LiveOps Wins Silver At The 2014 Brandon Hall Group Excellence In Learning Awards For Best Use Of Social/Collaborative Learning 4Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 2Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 3Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 2Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 3Health News:Poor body size judgement can lead to increased tolerance of obesity 2Health News:ESMO 2014 Congress Preview 2
... Chief Financial Officer, OAKLAND, Calif., July 1 ... ("WorldHeart" or the "Corporation") announced today,that, on June ... NASDAQ Stock,Market stating that the Corporation does not ... requires the Corporation to maintain,a minimum market value ...
... Somanetics Corporation,(Nasdaq: SMTS ) announced today that ... up to an additional $15 million of its common,shares ... shares). Purchases may be,made from time to time in ... timing and amount of, and purposes for, any,purchases will ...
... development, researcher says , , TUESDAY, July 1 (HealthDay News) ... numerous painful interventions, not enough is being done to ... 42,413 painful procedures included in this study, only 2 ... percent received non-pharmacological pain therapy. That means about four ...
... PHILADELPHIA - Researchers at the University of Pennsylvania School ... vaccinate against avian flu. By delivering vaccine via DNA ... minute electric pulse, researchers have immunized experimental animals against ... for the build up of vaccine reserves that could ...
... July 1, 2008 Researchers have found that a ... varieties of adult rheumatoid arthritis is also present in ... responsible gene may be a "master switch" that helps ... Children,s Hospital of Philadelphia reported on the link between ...
... close to patient pinpointed who was likely to progress to ... questionnaire may help in both diagnosing older adults facing dementia ... living. , The Everyday Cognition instrument consists of 39 questions ... , "There have been a number of studies that show ...
Cached Medicine News:Health News:WorldHeart Receives Non-Compliance Letter From NASDAQ Stock Market 2Health News:WorldHeart Receives Non-Compliance Letter From NASDAQ Stock Market 3Health News:Somanetics Announces Share Repurchase Program Increased By $15 Million 2Health News:Newborns in Intensive Care Often Exposed to Pain 2Health News:Newborns in Intensive Care Often Exposed to Pain 3Health News:Penn animal study identifies new DNA weapon against avian flu 2Health News:Penn animal study identifies new DNA weapon against avian flu 3Health News:Pediatric researchers find possible 'master switch' gene in juvenile arthritis 2Health News:Mental Test Spots Alzheimer's Risk 2Health News:Mental Test Spots Alzheimer's Risk 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: